Current diabetes reviews最新文献

{"title":"Gliflozin-Derived SGLT2 Inhibitors: Recent Advances and Future Perspectives in the Management of Type 2 Diabetes.","authors":"Biswanath Prusty, Sudhansu Sekhar Rout, Abhijit Saha","doi":"10.2174/0115733998505609261006104914","DOIUrl":"https://doi.org/10.2174/0115733998505609261006104914","url":null,"abstract":"<p><p>Gliflozin derivatives, a class of Sodium-Glucose Cotransporter (SGLT) inhibitors, have emerged as effective antidiabetic agents offering notable cardiovascular and renal protection. This class of compounds inhibits glucose reabsorption in the kidneys, thereby improving overall glycaemic control. This review provides a comprehensive overview of gliflozin derivatives, emphasizing their chemical characterization, safety, therapeutic efficacy, pharmacokinetic analysis, and potential future applications, focusing on clinical trials and new developments released between 2010 and 2026. Gliflozin derivatives slow the progression of chronic kidney disease and reduce the risk of heart failure. Some preliminary experimental evidence has reported the antibacterial activity of canagliflozin against MRSA. The Gliflozin derivatives dapagliflozin (IC50 =1.1nM), ertugliflozin (IC50 =0.9nM), sotagliflozin (IC50 =1.8nM), and bexagliflozin (IC50 =2.3nM), which has core motif, 1-chloro-2-(4-alkoxy benzyl) benzene as an aglycon unit and a glycon unit bind with SGLT2 receptor and lowered the HbA1c by 1.2%, 1.7%, 0.41% and 0.80%, respectively. Its selectivity, pharmacokinetics, and toxicity profiles are also optimal. Recent studies have demonstrated their involvement in conditions other than diabetes, including obesity, non-alcoholic fatty liver disease, Cardioprotective, Nephroprotective, Anti-inflammatory, and antihypertensive effects. Gliflozin derivatives represent a paradigm shift in the management of diabetes and have broad therapeutic potential. Future studies should emphasize creative structural changes to increase safety and efficacy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronotherapeutic and Circadian Rhythm-Based Strategies in Diabetes Management: A Critical Opinion Based on Evidences.","authors":"Vijay Singh, Neeraja Suresh, Sapna Saini, Shailendra Dwivedi, Akash Bansal","doi":"10.2174/0115733998495346261007070830","DOIUrl":"https://doi.org/10.2174/0115733998495346261007070830","url":null,"abstract":"<p><p>Diabetes mellitus is one of the world's leading health problems, and standard approaches to therapy do not take into consideration the impact of circadian misalignment on metabolic health. Chronobiological processes are involved in regulating glucose homeostasis, insulin release, hepatic glucose production, lipids, and energy metabolism; hence, disruptions such as those caused by non-rhythmic sleep patterns, shifts at work, irregular meal times, and light exposure could cause insulin resistance and even type 2 diabetes. The current critical review discusses the light-melatonin interaction and personalized chronobiological medicine. Instead of giving a descriptive account of particular treatments, the paper introduces the integrative importance of chronobiology for the management of diabetes by considering data about chrononutrition, time-restricted feeding, chronopharmacology, chrono-exercise, and an approach to chronometabolism based on the integration of the timing of meals, drugs, exercise, sleep, and light exposure with chronotype, metabolic phenotype, and the feasibility of the therapy. Circadian timing can be a promising adjuvant in the treatment of diabetes; however, the available evidence does not suggest an ideal time for intervention. Further studies should focus on measuring time, well-powered randomized controlled trials, long-term outcomes, and individualization of chronotherapy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing Artificial Intelligence-driven Approaches in the Diagnosis and Management of Diabetes and Diabetes-Associated Complications.","authors":"Yachana Mishra, Rajeev Kanday, Simran Kauts, Sheetu Wadhwa, Aditi Chattaraj, Alaa A A Aljabali, Altijana Hromić-Jahjefendić, Vladimir N Uversky, Vijay Mishra","doi":"10.2174/0115733998484763260928100503","DOIUrl":"https://doi.org/10.2174/0115733998484763260928100503","url":null,"abstract":"<p><p>Diabetes mellitus is a global health issue with escalating metabolic dysfunction, clinical heterogeneity, and rising microvascular and macrovascular consequences. Traditional diabetes diagnosis, risk assessment, treatment selection, and complication surveillance rely on periodic clinical measures and population-level risk models, which may not fully capture dynamic, individualized disease pathways. Precision diabetes treatment is being transformed by Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and multimodal data analytics. This review critically examines AI-driven approaches to diabetes management, including early disease prediction, diagnostic support, glycemic monitoring, treatment-response prediction, and the prevention and detection of diabetes-associated complications. The US Food and Drug Administration (USFDA) has sanctioned multiple AI/ML-based medical devices for automated retinal screening, clinical diagnostic assistance, and patient self-management applications. For clinically meaningful patterns and disease progression prediction, AI-enabled analysis of continuous glucose monitoring data, retinal images, electronic health records, wearable device signals, laboratory parameters, and multi-omics datasets is prioritized. The use of AI for detecting diabetic retinopathy, kidney disease, cardiovascular disease, neuropathy, and foot disorders is also highlighted.Data quality, algorithmic bias, interpretability, privacy, cybersecurity, model drift, regulatory monitoring, clinical validation, and equitable access prevent widespread application despite promising results. This study offers a thorough and critical assessment of the developing roles of AI, specifically ML and DL, in the prediction, diagnosis, and management of diabetes and its related complications. Real-world validation, standardized evaluation frameworks, trustworthy AI, and effective human- AI collaboration will drive advancement. AI could transform diabetes management into predictive, tailored, continuous, and complication-preventive care.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Metformin on Thyroid Function in Patients with Type 2 Diabetes, Subclinical Hypothyroidism, and Insulin Resistance: A Systematic Review and Meta-Analysis.","authors":"Hossein Nezami, Alireza Amirabadizadeh, Mahdi Abdesheikhi, Ahmadreza Baghestani, Habibollah Esmaily","doi":"10.2174/0115733998496363260914080851","DOIUrl":"https://doi.org/10.2174/0115733998496363260914080851","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Metformin, the first-line therapy for type 2 diabetes and insulin resistance, has been reported to affect thyroid function, particularly Thyrotropin (TSH), although results for other thyroid hormones are inconsistent. We therefore performed a systematic review and meta-analysis to evaluate the effects of metformin on serum TSH, FT4, FT3, total T4, and total T3 levels compared with placebo in patients with type 2 diabetes, insulin resistance, and subclinical hypothyroidism.</p><p><strong>Methods: </strong>A systematic search of PubMed, Scopus, Web of Science, and Google Scholar was conducted from inception to November 2025 to identify randomized controlled trials and observational studies evaluating the effects of metformin on thyroid hormone parameters compared with placebo. Pooled mean differences with 95% confidence intervals were calculated using random-effects models. Heterogeneity was assessed using the I2 statistic, and publication bias was evaluated using Begg's test. Sensitivity analyses were performed to assess the robustness of the pooled estimates.</p><p><strong>Results: </strong>A total of 13 studies including 1,178 participants were included in the meta-analysis. In patients with type 2 diabetes, metformin therapy was associated with a statistically significant reduction in serum FT3 concentrations compared with placebo (MD= -0.44; 95% CI: -0.79 to -0.10; p = 0.01), whereas no significant change in serum TSH levels was observed (MD = -0.38; 95% CI: -1.05 to 0.41; p = 0.39); FT4 and total T4 levels also remained unchanged. Among patients with subclinical hypothyroidism, metformin treatment was not associated with significant changes in TSH or FT4 concentrations.</p><p><strong>Discussion: </strong>Metformin appears to have limited effects on thyroid-related parameters in patients with type 2 diabetes and subclinical hypothyroidism. The observed reduction in FT3 levels, in the absence of consistent changes in TSH or FT4, may indicate that the changes observed in thyroid hormone profiles are limited and should be interpreted considering the clinical context and variability among included studies.</p><p><strong>Conclusion: </strong>Current evidence suggests that metformin does not significantly modify overall thyroid function in patients with type 2 diabetes, subclinical hypothyroidism, or insulin resistance. Further studies are needed to clarify its potential effects in specific patient populations.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Pediatric Glycemic Control with Smart Insulin Pens: The Current Trends and Future Prospects.","authors":"Hadia Hannan, Fares Mohammad, Khaled Chahrour, Banan Mohgoub, Nour M Al Sawaftah, Kelly M Percival, Ghaleb A Husseini","doi":"10.2174/0115733998468232260917101115","DOIUrl":"https://doi.org/10.2174/0115733998468232260917101115","url":null,"abstract":"<p><p>Pediatric diabetes management remains challenging, as many young patients struggle to hit glycemic targets due to developmental factors and treatment burdens. Smart insulin pens are a game-changing \"connected MDI\" alternative, with \"pump-like\" features such as bolus calculators and automated Insulin-on-Board tracking for non-pump users. This review explores the clinical effectiveness, economic impact, and prospects of SIPs in pediatrics, including patient and caregiver insights and long-term effects on glycemic control. Caregivers and patients agree SIPs are accessible and easy to use due to user-friendly interfaces, data-driven approaches, and remote monitoring. Evidence shows SIPs improve safety and adherence, with a 31.4% reduction in daily hypoglycemia, a 24.4% decrease in nocturnal hypoglycemia, and a drop in Time Below Range Level 2 from 2.82% to 2.18%. By tracking insulin-on-board, SIPs prevent insulin stacking and enable safe correction doses; users correcting within three hours of a previous dose spend more time in range without increased hypoglycemia. SIPs also cut missed boluses by up to 43% in youth. Economically, SIPs save about SEK 124,270 per patient by delaying complications. However, adoption remains limited due to socioeconomic barriers, with 82% of clinics citing insurance issues and lower use among Medicaid beneficiaries. Barriers include the learning curve and device costs, which can be addressed through subsidies and training programs. Future AI developments, like hypoglycemia prediction, promise to further personalize pediatric care. Overall, SIPs benefit pediatric diabetes management, but more research, including clinical trials, is needed to confirm optimal outcomes.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiRNAs-Mediated Regulation of Oxidative Stress Pathways in Diabetes Complications: Molecular Insights and Therapeutic Opportunities.","authors":"Prachitee Borkar, Neetu Mishra","doi":"10.2174/0115733998428699260903053740","DOIUrl":"https://doi.org/10.2174/0115733998428699260903053740","url":null,"abstract":"<p><p>Persistent hyperglycemia and uncontrolled type 2 diabetes contribute significantly to diabetes- related mortality by causing multiorgan and systemic injuries, particularly in vital organs such as the heart and kidneys, leading to both microvascular and macrovascular complications. The auto-oxidation of glucose increases oxidative stress, which in turn affects gene modulation and immune responses through the activation of four major pathways: (1) the polyol pathway, (2) the protein kinase C (PKC) pathway, (3) the advanced glycation end-product-receptor for advanced glycation end-product (AGE-RAGE) pathway, and (4) the hexosamine pathway. Oxidative stress and microRNAs (miRNAs) are closely related. These small non-coding RNAs bind to the 3' untranslated regions (3' UTRs) of target mRNAs, leading to mRNA degradation and translational repression. Although numerous studies have identified microRNAs (miRNAs) as important regulators of oxidative stress and diabetic complications, the available evidence remains fragmented. Therefore, this review aims to discuss the roles of miRNAs in oxidative stress-activated pathways and in the generation and detoxification of reactive oxygen species. It also highlights the potential of miRNAs as novel therapeutic targets in type 2 diabetes mellitus and outlines the challenges associated with their clinical application.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-label Use of the Tandem t: slim X2™ with Control IQ® in Pregnancy: Insights from Five Case Studies.","authors":"Ana Rita Leite, Rita Lopes, Patrícia Ferreira, Gabriela Namora, Cristina Gamboa, Joana Queirós, João Sérgio Neves, Sandra Belo","doi":"10.2174/0115733998507589260907041440","DOIUrl":"https://doi.org/10.2174/0115733998507589260907041440","url":null,"abstract":"<p><strong>Introduction/background: </strong>Hybrid closed-loop systems (HCLS), such as the Tandem t: slim X2™, are widely used in patients with type 1 diabetes mellitus (T1DM) and have well-established benefits in glycemic control. However, evidence supporting their use during pregnancy and the peripartum period remains limited.</p><p><strong>Case presentation: </strong>We conducted a descriptive observational case series from August 2024 to February 2026 of five pregnant women with T1DM using the Tandem t: slim X2™ with Control- IQ® off-label during pregnancy, labor, and the early postpartum period. Glycemic control improved during pregnancy, with mean TIRp increasing from 50.9±17.9% before HCLS initiation to 61.0±14.4% in the third trimester, alongside a reduction in HbA1c from 7.2±1.0% to 6.0±0.5%. Preeclampsia occurred in three of the five cases. In Cases 1 to 4, HCLS remained in automated mode during labor and delivery, with Sleep Activity activated for 33%-40% of the time and latethird- trimester settings maintained. Case 5 suspended HCLS before labor and restarted two days postpartum. Mean pregnancy-specific time in range (TIRp) during labor and delivery was 64.3±10.7%, with minimal hypoglycemia (1.5±2.6%). Early postpartum period (days 1-3) mean TIR was 80.8±14.6%, and time below range (TBR) was 2.3±1.1%. Neonatal hypoglycemias were reported in three of the five cases.</p><p><strong>Conclusion: </strong>This case series suggests that Tandem t: slim X2™ Control-IQ® is safe and may improve glycemic control during pregnancy and the peripartum period. Further studies comparing this approach with standard care are needed to comprehensively evaluate its effects on glycemic control and maternal and neonatal outcomes.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the Potential of Yellow Kepok Banana Peel Extract: An Innovative Solution for Treating Metabolic Disorders in Rabbits with Hyperlipidemia and DM.","authors":"Amin Samiasih, Yunan Kholifatuddin Sya'di, Dyah Nirmala Arum Janie, Nurul Qurrota Ayun, Lita Rakhma Yustinasari","doi":"10.2174/0115733998484722260907044221","DOIUrl":"https://doi.org/10.2174/0115733998484722260907044221","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus is associated with chronic hyperglycemia, dyslipidemia, and systemic inflammation. Banana peel contains bioactive compounds with antioxidant and anti-inflammatory properties and may provide a natural therapeutic alternative. This study aimed to evaluate its potential effects on metabolic and inflammatory parameters in rabbits with HFFD-induced metabolic disturbances.</p><p><strong>Method: </strong>This preclinical experimental study involved 40 male New Zealand White rabbits (3-4 months; 1.5-2.0 kg) randomly assigned to four groups (n = 10): Healthy Control, HFFD control (HFFD-induced diabetes mellitus), and two treatment groups receiving either 0.3% sodium carboxymethyl cellulose (NaCMC) or banana peel extract (200 mg/kg body weight). Diabetes and hyperlipidemia were induced using a high fructose fat diet (HFFD) for two weeks, followed by a three-week treatment period. Blood samples were collected at baseline, post-induction, and posttreatment to measure glucose, triglycerides, and inflammatory markers (hsCRP and IL-10) using biochemical assays and ELISA. Histological evaluation was performed on tissue samples. Data were analysed using One-Way ANOVA or the Kruskal-Wallis test based on data distribution, with post hoc analysis and a significance level of p < 0.05.</p><p><strong>Results: </strong>Yellow banana peel extract (200 mg/kgBW) significantly reduced fasting blood glucose, triglycerides, and hsCRP levels while increasing IL-10 expression, indicating antidiabetic and anti- inflammatory effects in an HFFD-induced diabetic model.</p><p><strong>Discussion: </strong>The findings suggest that yellow kepok banana peel extract exhibits significant antihyperlipidemic and antidiabetic potential, which may be attributable to bioactive compounds previously reported in banana peel, which may improve lipid metabolism and glucose regulation.</p><p><strong>Conclusion: </strong>Banana peel extracts showed potential as a supportive natural adjunct for improving glucose and lipid profiles in patients with diabetes mellitus. These findings suggest that extract- based natural products may improve metabolic control and reduce cardiovascular risk. Further studies are required to elucidate the underlying mechanisms and to confirm long-term safety and efficacy in clinical settings.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Imeglimin as a Novel Therapeutic Action Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","authors":"Samyuktha Krishnamoorthy, Sarumathy Sundararajan","doi":"10.2174/0115733998495947260828082811","DOIUrl":"https://doi.org/10.2174/0115733998495947260828082811","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Imeglimin is the first agent of the novel glimin class that targets mitochondrial dysfunction, a key pathophysiological mechanism underlying type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of imeglimin in patients with T2DM.</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed, Scopus, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from database inception to December 2025. Randomized controlled trials (RCTs) and prospective observational studies evaluating imeglimin as monotherapy or combination therapy were included. Risk of bias was assessed using the Cochrane RoB 2.0 and ROBINS-I tools. Continuous outcomes were pooled as mean differences (MDs) and dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Twenty-four studies were included in the qualitative synthesis, comprising 13 experimental studies and 11 observational studies. Thirteen RCTs involving 1,925 participants were eligible for quantitative meta-analysis. Imeglimin significantly reduced glycated haemoglobin (HbA1c) compared with control therapy (MD -0.21%; 95% CI: -0.25 to -0.17), although substantial heterogeneity was observed (I2 = 96.1%). Fasting plasma glucose (FPG) was also significantly reduced (MD -0.97 mmol/L; 95% CI: -1.08 to -0.86; I2 = 92.3%). No statistically significant increase in serious adverse events was identified. Gastrointestinal adverse events were primarily dose-related and generally mild. Although the pooled analysis showed an increased risk of hypoglycaemia, subgroup analyses were limited by low event rates and wide confidence intervals.</p><p><strong>Discussion: </strong>Imeglimin demonstrated consistent improvements in glycaemic control, particularly when used in combination with other antidiabetic therapies. Variations in study design, treatment duration, baseline glycaemic status, and comparator regimens likely contributed to the observed heterogeneity.</p><p><strong>Conclusion: </strong>Imeglimin is an effective glucose-lowering therapy with an acceptable safety profile in patients with T2DM. Optimal efficacy appears to be achieved at doses of 1000-1500 mg twice daily, particularly as add-on therapy. Further large-scale, long-term studies are required to evaluate cardiovascular and renal outcomes and establish its role in routine clinical practice.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Patients' Perspectives on Self-Management Behaviors and Influencing Factors in Chronic Disease Management.","authors":"Bakur O Aljedani, Shafeah M Aljedaani, Nisreen G Fintyanh, Ali A Theban, Najla S Alotaibi, Ayman A Bafaqeeh","doi":"10.2174/0115733998486162260805073507","DOIUrl":"https://doi.org/10.2174/0115733998486162260805073507","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Self-management is essential for chronic disease control. This study aimed to explore patients' perspectives on self-management behaviors and the factors influencing these behaviors in chronic disease management.</p><p><strong>Methods: </strong>A descriptive analytical cross-sectional study was conducted in primary healthcare centers affiliated with Jeddah's Second Health Cluster. Using simple random sampling, 123 adults with controlled type 2 diabetes, controlled hypertension, or both conditions were recruited. Data were collected through telephone interviews using a validated questionnaire.</p><p><strong>Results: </strong>Overall self-management was high (mean = 2.65; 82.5%). The highest-rated behaviors were medication adherence (93%), adherence to treatment recommendations (91.5%), and appointment attendance (90%). Symptom monitoring, contact with the healthcare team, and monitoring at primary healthcare centers were also high (≥82.5%). Dietary adherence and physical activity were moderate (72% each). Influencing factors were high for knowledge/awareness (84%-89%), intrinsic motivation (81.5%), self-efficacy (83.5%), problem-solving ability (80.5%), and social/family support (84.5%). Stress-management coping capacity (69.5%) and post-appointment follow-up (61%) were moderate. Self-management was higher among participants without comorbidities, non-smokers, and those living with family (p < 0.05), positively associated with disease duration and education, and negatively associated with age.</p><p><strong>Discussion: </strong>Self-management was strongest when embedded in treatment routines and supported by personal capability and family support, whereas sustaining lifestyle change and psychological coping remained more challenging.</p><p><strong>Conclusion: </strong>Among adults with controlled type 2 diabetes, controlled hypertension, or both conditions, self-management was generally high and supported by enabling factors, but with limited generalizability. Targeted, patient-centered interventions are needed to strengthen lifestyle self-management, psychological coping, and structured follow-up.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}